Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab
von Bubnoff D, Schmitt C, Goldinger SM, Schadendorf D, Kähler KC, Hafner C, Kramer N, Fröhlich W, Dummer R, Berking C, Schliep S, Kirchberger M, Heinzerling L (2025)
Publication Type: Journal article
Publication year: 2025
Journal
Book Volume: 20
Article Number: e0321937
Journal Issue: 5 May
DOI: 10.1371/journal.pone.0321937
Abstract
Background The tumor microenvironment is crucial for prognosis and response to immunotherapy in several tumor entities. Methods In a multicenter retrospective study, a total of 86 tumor samples from patients with metastatic melanoma were evaluated for baseline expression of indoleamine 2,3-dioxygenase (IDO) and programmed death ligand 1 (PD-L1). Expression patterns of IDO and PD-L1 on tumor cells and antigen-presenting cells (APCs) as determined by immunohistochemical (IHC) staining of paraffin-embedded tissue sections were correlated with response to ipilimumab and overall survival (OS). Statistical analysis was performed using the Spearman correlation, the Mann-Whitney test and Kaplan-Meier estimator. Results IDO expression in tumor cells or APCs was not predictive for treatment response. The median OS was 26 months in IDO-positive and IDO-negative patients, regardless of IDO expression in tumor cells or APCs. A correlation of IHC expression scores of IDO and PD-L1 could not be documented. Conclusion The exact role of IDO in creating an immunosuppressive tumor environment and its reversal needs to be further elucidated.
Authors with CRIS profile
Carola Berking
Lehrstuhl für Haut- und Geschlechtskrankheiten
Michael Kirchberger
Department of Dermatology
Lucie Heinzerling
Department of Dermatology
Involved external institutions
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Klinikum der Universität München
Germany (DE)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
Germany (DE)
Klinikum der Universität München
Germany (DE)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Universitätsklinikum Essen
Germany (DE)
Universitätsklinikum Regensburg
Germany (DE)
How to cite
APA:
von Bubnoff, D., Schmitt, C., Goldinger, S.M., Schadendorf, D., Kähler, K.C., Hafner, C.,... Heinzerling, L. (2025). Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab. PLoS ONE, 20(5 May). https://doi.org/10.1371/journal.pone.0321937
MLA:
von Bubnoff, Dagmar, et al. "Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab." PLoS ONE 20.5 May (2025).
BibTeX: Download